A Phase III Trial of AK112 in Advanced Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-17
Target enrollment:
Participant gender:
Summary
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical
therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG)
performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of
AK112 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed
cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.